A bumetanide composition and preparation method thereof
Through the airflow pulverization and boiling granulation process, combined with the use of magnesium oxide and megamine, the problem of N-nitrosamine impurities in the bumetanib preparation was solved, and the safety and effectiveness of the drug were significantly improved.
Patent Information
- Application Number
- CN202411179041.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-27
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2044-08-27
AI Technical Summary
During storage, the existing bumetanib preparations are prone to react with the nitrite in the auxiliary materials to form N-nitrosamine bumetanib impurities, resulting in an increased risk of carcinogenicity. The common antioxidants have poor stability and introduce new unknown impurities. Impacts the safety and effectiveness of the drug.
Use airflow crusher to crush mattematani with part of talc and part of silica, mixed magnesium oxide and megamine as stabilizers, and control particle size D90≤30μm through boiling granulation process, increase the surface area of the raw material, and ensure alkalization. Effective contact of agent auxiliary materials reduces the production of N-nitrosamine bumetani impurities.
It significantly reduces the generation of N-nitrosamine Bumetani impurities, ensures the safety and effectiveness of the drug during storage, and improves the safety and effectiveness of the drug.
Smart Images

Figure SMS_2 
Figure SMS_3 
Figure SMS_4
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of pharmaceutical preparations, and in particular to a bumetanide composition and a preparation method thereof. Background Art
[0002] Nitrosamines refer to a class of small molecule compounds in which nitroso groups are directly linked to amines. In the metabolic environment of the body, nitrosamines can be converted into alkyl diazonium ions and directly interact with nitrogen and oxygen in molecules such as guanine, cytosine and thymine that make up DNA, alkylating DNA, causing mismatches and mutations in DNA and creating a risk of cancer. This type of impurity is not only difficult to remove, but its content in drugs continues to increase with prolonged storage time.
[0003] Bumetanide is a derivative of m-aminobenzenesulfonamide. Its plasma content reaches a peak 1 to 2 hours after oral administration. It is mainly metabolized by the liver and exerts a diuretic effect by inhibiting the active reabsorption of chloride ions and the passive reabsorption of sodium ions by the loop of Henle. It is a common and potent diuretic in clinical practice. Bumetanide has a secondary amine structure in its structure. During the production and storage of the preparation, it is very easy to react with the nitrite contained in the excipients to form N-nitrosamine bumetanide impurities, which increases the risk of patients using the drug. Its chemical reaction is as follows:
[0004] .
[0005] According to literature reports, adding antioxidants such as vitamin C, caffeic acid, ferulic acid, etc. to the formulation of bumetanide tablets has a certain effect on inhibiting the growth of N-nitrosamine bumetanide impurities, but it still cannot avoid the increase of this impurity during the stability process. In addition, the above-mentioned ingredients themselves have poor stability and introduce other new unknown impurities due to their own degradation during storage, facing more safety challenges.
[0006] Invention patent CN 101451799 B discloses a pharmaceutical composition with pravastatin as the main ingredient, which changes the pH value of the product by adding meglumine to avoid the degradation of pravastatin in an acidic environment. However, for bumetanide, simply adding a small amount of meglumine is not ideal for inhibiting the increase of N-nitrosamine bumetanide impurities. When the dosage of meglumine is increased, the pH value will be higher, which may cause changes in the pH environment in the body during use, thereby affecting the safety and effectiveness of medication.
[0007] Therefore, how to inhibit the generation of N-nitrosamine bumetanide impurities during the preparation and storage process is the focus of current research.
[0008] In view of this, the present invention is proposed. Summary of the invention
[0009] The object of the present invention is to provide a bumetanide composition and a preparation method thereof.
[0010] The present invention is achieved in that:
[0011] In a first aspect, the present invention provides a method for preparing a bumetanide composition, wherein the raw materials of the bumetanide composition include bumetanide: microcrystalline cellulose: corn starch: povidone: stabilizer: talc: silicon dioxide: Tween 80: magnesium stearate in a mass ratio of 1:40-80:80-140:4-12:4-9:4-10:6-10:0.5:0.5-2.5; the stabilizer includes magnesium oxide and meglumine;
[0012] The preparation method comprises:
[0013] S1: Bumetanide, part of talc, and part of silicon dioxide are preliminarily mixed, and then crushed by a jet mill to a particle size D90≤30 μm to obtain a primary mixed raw material;
[0014] S2: mixing the primary mixed raw materials, microcrystalline cellulose, corn starch, povidone, stabilizer, and Tween 80 for boiling granulation to obtain blended granules;
[0015] S3: granulating the blended particles, adding the remaining talcum powder, the remaining silicon dioxide and magnesium stearate after granulating, and mixing them evenly to obtain a granular product.
[0016] In an optional embodiment, the mass ratio of magnesium oxide to meglumine in the stabilizer is 1-10:1-3.
[0017] In an optional embodiment, the mass ratio of magnesium oxide to meglumine in the stabilizer is 5 to 8:1.
[0018] In an optional embodiment, obtaining the blended particles in step S2 comprises:
[0019] The primary mixed raw materials, microcrystalline cellulose, corn starch, povidone and magnesium oxide are first subjected to wet granulation to obtain first granules;
[0020] Then, the first granules are placed in a fluidized bed granulation pot, and after the temperature of the first granules is controlled at 35-45° C., Tween 80 solution is sprayed into the granules to perform boiling granulation;
[0021] The meglumine is added as dry powder during wet granulation, or prepared as a solution during boiling granulation and added together with the Tween 80.
[0022] In an optional embodiment, the stirring speed during the wet granulation is 300-500 rpm, the shear speed is 1000-1500 rpm, and the mixing time is 10-30 min.
[0023] In an optional embodiment, during the boiling granulation, the material temperature is maintained at 25°C to 42°C; after the liquid spraying is completed, the inlet air temperature is maintained at 70°C to 80°C, and after the moisture content of the particles is controlled at 4% to 8%, the drying is stopped and the material is collected.
[0024] In an optional embodiment, the granulation comprises passing the blended particles through a 20-40 mesh sieve.
[0025] In an optional embodiment, the amount of some of the talc powder accounts for 30%-50% of the total amount of the talc powder, and the amount of some of the silicon dioxide accounts for 20%-40% of the total amount of the silicon dioxide.
[0026] In a second aspect, the present invention provides a bumetanide composition, which is prepared by the preparation method described in any one of the aforementioned embodiments.
[0027] In an optional embodiment, the bumetanide composition is in the form of granules, capsules or tablets.
[0028] The present invention has the following beneficial effects:
[0029] The preparation method of the bumetanide composition provided by the present invention improves the raw materials and methods, adds a small amount of magnesium oxide and meglumine as a stabilizer, and grinds bumetanide, part of talcum powder, and part of dioxide by a jet mill, so that a primary mixed raw material with a particle size D90≤30μm can be obtained. By controlling the particle size of the primary mixed raw material, it is beneficial to increase its surface area and ensure that the raw material and the alkalizing agent excipient are in more effective contact; then boiling granulation is performed with other excipients, so that the N-nitrosamine bumetanide impurities of the product can be significantly reduced during the preparation process and subsequent stability placement process. Under various investigation conditions, the N-nitrosamine bumetanide impurities have no significant changes compared with 0 days, ensuring the safety of the product. The generation of N-nitrosamine bumetanide impurities during the preparation and storage process can be effectively inhibited, and the safety and effectiveness of the medication can be significantly improved. DETAILED DESCRIPTION
[0030] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.
[0031] The present invention has been found in the research process that the generation of N-nitrosamine bumetanide impurities in bumetanide is caused by the following reasons:
[0032] (1) Nitrite exists in various excipients, and the content varies greatly. Excipient manufacturers do not perform quality control on nitrite during the production process. When bumetanide comes into contact with nitrite in the excipients, N-nitrosamine bumetanide impurities will be generated;
[0033] (2) Although the use of antioxidants can inhibit the growth of N-nitrosamine bumetanide impurities, it is well known that antioxidants themselves have poor stability and are easily degraded, so they will introduce new unknown impurities, posing challenges to safety issues.
[0034] (3) During the preparation process of bumetanide tablets, they will be in a high temperature and high humidity state for a long time, which will aggravate the N-nitrosamine bumetanide. Simply adding magnesium oxide or meglumine to the prescription cannot effectively inhibit the increase of N-nitrosamine bumetanide impurities during the preparation and storage process. Excessive addition of the above-mentioned alkalizing agents will lead to a high pH value, bringing risks to safety and effectiveness.
[0035] To this end, the present invention provides a method for preparing a bumetanide composition, wherein the raw materials of the bumetanide composition include bumetanide: microcrystalline cellulose: corn starch: povidone: stabilizer: talc: silicon dioxide: Tween 80: magnesium stearate in a mass ratio of 1:40-80:80-140:4-12:4-9:4-10:6-10:0.5:0.5-2.5; the stabilizer includes magnesium oxide and meglumine. Preferably, the mass ratio of magnesium oxide to meglumine in the stabilizer is 1-10:1-3. Further preferably, the mass ratio of magnesium oxide to meglumine in the stabilizer is 5-8:1.
[0036] In the present invention, a small amount of magnesium oxide and meglumine are mixed and added as stabilizers, and a specific process is combined to effectively inhibit the generation of N-nitrosamine bumetanide impurities during the preparation and storage process, thereby significantly improving the safety and effectiveness of the medication.
[0037] Specifically, the preparation method includes:
[0038] S1: Bumetanide, part of talc, and part of silicon dioxide are preliminarily mixed, and then crushed by a jet mill to a particle size D90≤30 μm to obtain a primary mixed raw material;
[0039] S2: mixing the primary mixed raw materials, microcrystalline cellulose, corn starch, povidone, stabilizer, and Tween 80 for boiling granulation to obtain blended granules;
[0040] S3: The blended granules are granulated, and after the granulation is completed, the remaining talcum powder, the remaining silicon dioxide and magnesium stearate are added, and the mixture is mixed evenly to obtain a granular product.
[0041] In the present invention, bumetanide, part of talc and part of dioxide are pulverized by a jet mill to obtain a primary mixed raw material with a particle size D90≤30 μm. By controlling the particle size of the primary mixed raw material, it is beneficial to increase its surface area and ensure more effective contact between the raw material and the alkalizing agent auxiliary material; then boiling granulation is performed with other auxiliary materials, so that the N-nitrosamine bumetanide impurity of the product can be significantly reduced during the preparation process and the subsequent stability placement process. Under various investigation conditions, the N-nitrosamine bumetanide impurity has no significant change compared with 0 day, thereby ensuring the safety of the product.
[0042] In some other embodiments of the present invention, the amount of the partial talc in step S1 accounts for 30%-50% of the total amount of talc, and the amount of the partial silicon dioxide accounts for 20%-40% of the total amount of silicon dioxide.
[0043] In some other embodiments of the present invention, obtaining the blended particles in step S2 comprises:
[0044] (1) The primary mixed raw materials, microcrystalline cellulose, corn starch, povidone and magnesium oxide are first wet granulated to obtain first granules.
[0045] The stirring speed during wet granulation is 300-500 rpm, the shear speed is 1000-1500 rpm, and the mixing time is 10-30 min.
[0046] (2) The first granules are then placed in a fluidized bed granulation pot, the temperature of the first granules is controlled at 35-45°C, and then Tween 80 solution is sprayed into the granules to perform boiling granulation.
[0047] During boiling granulation, the material temperature is maintained at 25℃~42℃; after the spraying is completed, the inlet air temperature is maintained at 70~80℃, and after the moisture content of the particles is controlled at 4%~8%, the drying is stopped and the material is collected.
[0048] Preferably, during boiling granulation, the material temperature is maintained at 25°C to 30°C; after the liquid spraying is completed, the inlet air temperature is maintained at 70°C to 80°C, and after the moisture content of the particles is controlled at 4% to 6%, the drying is stopped and the material is collected.
[0049] There are many options for adding meglumine, for example, meglumine can be added as dry powder during wet granulation, or prepared as a solution and added together with Tween 80 during boiling granulation.
[0050] In some other embodiments of the present invention, the granulation in step S3 includes passing the blended particles through a 20-40 mesh sieve. After the granulation is completed, talcum powder, silicon dioxide, and magnesium stearate are added, and a three-dimensional motion mixer is used to mix at a speed of 8-12 rpm for 8-12 minutes, and the material is discharged.
[0051] It should be understood that the material obtained in step S3 is granules, and the bumetanide composition provided by the present invention can be adjusted into different dosage forms according to actual conditions, such as granules, capsules or tablets.
[0052] When the bumetanide composition is a capsule or tablet, the granules need to be prepared into capsules or tablets. Taking tablets as an example, the granules are compressed into tablets using a rotary tablet press and the compression hardness is controlled to be 40 to 80N.
[0053] The preparation method of the bumetanide composition provided by the present invention comprises mixing bumetanide, part of talc powder and part of silicon dioxide and performing air flow milling to control the particle size of the blended raw materials, and then the blended raw materials and other auxiliary materials are subjected to high shear mixing, fluidized bed boiling granulation, and then mixed with other auxiliary materials and then tableted. The process can effectively inhibit the generation of N-nitrosamine bumetanide impurities by bumetanide during the preparation production process (high temperature and high humidity environment), and at the same time ensure that the N-nitrosamine bumetanide impurities within the validity period meet the limit control requirements. The bumetanide composition prepared by the preparation method of the bumetanide composition has a low impurity content.
[0054] The excipients involved in the prescription of the present invention are all commonly used excipients, and the preparation process is a commonly used preparation production process, which is suitable for commercial production. At the same time, the present invention will bring patients safer and more effective preparations.
[0055] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.
[0056] Example 1
[0057] This embodiment provides a method for preparing a bumetanide composition, wherein the raw materials include:
[0058]
[0059] The preparation method thereof comprises:
[0060] Step 1: Preliminarily mix 2 g of bumetanide, 2 g of talc, and 2 g of silicon dioxide, and then grind them into a particle size D90≤30 μm using a jet mill to obtain a primary mixed raw material;
[0061] Step 2: Place 3 g of the primary mixed raw materials in step 1, microcrystalline cellulose, corn starch, povidone, magnesium oxide, and meglumine in a wet granulator, start stirring at a speed of 400 rpm and a shear speed of 1200 rpm and mix for 10 minutes;
[0062] Step 3: Dissolve the prescribed amount of Tween 80 in purified water and set aside;
[0063] Step 4: Place the material in step 2 in a fluidized bed granulation pot, control the material temperature at 40±5°C, and then start spraying the solution in step 3 to perform boiling granulation. The material temperature is controlled at 30±5°C. After the spraying is completed, maintain the inlet air temperature at 75°C, control the granule moisture content at 6%, stop drying, and collect the material.
[0064] Step 5: The granules in step 4 are sieved through a 30-mesh sieve for granulation. After granulation, talcum powder, silicon dioxide, and magnesium stearate are added, and a three-dimensional motion mixer is used to mix at a speed of 10 rpm for 10 minutes, and the material is discharged;
[0065] Step 6: The granules in step 5 are tableted using a rotary tablet press, and the tablet hardness is controlled at 60N.
[0066] Example 2
[0067] This embodiment provides a method for preparing a bumetanide composition, wherein the raw materials include:
[0068]
[0069] The preparation method thereof comprises:
[0070] Step 1: Preliminarily mix 2 g of bumetanide, 2 g of talc, and 2 g of silicon dioxide, and then grind them into a particle size D90≤30 μm using a jet mill to obtain a primary mixed raw material;
[0071] Step 2: Place 3 g of the primary mixed raw materials in step 1, microcrystalline cellulose, corn starch, povidone, and magnesium oxide in a wet granulator, start stirring at a speed of 400 rpm and a shear speed of 1200 rpm and mix for 10 minutes;
[0072] Step 3: Dissolve the prescribed amount of Tween 80 with an appropriate amount of purified water, and dissolve the prescribed amount of meglumine with an appropriate amount of purified water, and set aside;
[0073] Step 4: Place the material in step 2 in a fluidized bed granulation pot, control the material temperature at 40±5°C, and then start spraying the solution in step 3 to perform boiling granulation. The material temperature is controlled at 30±5°C. After the spraying is completed, maintain the inlet air temperature at 75°C, control the granule moisture content at 6%, stop drying, and collect the material.
[0074] Step 5: The granules in step 4 are sieved through a 30-mesh sieve for granulation. After granulation, talcum powder, silicon dioxide, and magnesium stearate are added, and a three-dimensional motion mixer is used to mix at a speed of 10 rpm for 10 minutes, and the material is discharged;
[0075] Step 6: The granules in step 5 are tableted using a rotary tablet press, and the tablet hardness is controlled at 60N.
[0076] Example 3
[0077] This embodiment provides a method for preparing a bumetanide composition, wherein the raw materials include:
[0078]
[0079] The preparation method thereof comprises:
[0080] Step 1: Preliminarily mix 2 g of bumetanide, 2 g of talc, and 2 g of silicon dioxide, and then grind them into a particle size D90≤15 μm using a jet mill to obtain a primary mixed raw material;
[0081] Step 2: Place 3 g of the primary mixed raw materials in step 1, microcrystalline cellulose, corn starch, povidone, and magnesium oxide in a wet granulator, start stirring at a speed of 400 rpm and a shear speed of 1200 rpm and mix for 30 minutes;
[0082] Step 3: Dissolve the prescribed amount of Tween 80 with an appropriate amount of purified water, and dissolve the prescribed amount of meglumine with an appropriate amount of purified water, and set aside;
[0083] Step 4: Place the material in step 2 in a fluidized bed granulation pot, control the material temperature at 40±5°C, and then start spraying the solution in step 3 to perform boiling granulation. The material temperature is controlled at 30±5°C. After the spraying is completed, maintain the inlet air temperature at 75°C, control the granule moisture content at 6%, stop drying, and collect the material.
[0084] Step 5: The granules in step 4 are sieved through a 30-mesh sieve for granulation. After granulation, talcum powder, silicon dioxide, and magnesium stearate are added, and a three-dimensional motion mixer is used to mix at a speed of 10 rpm for 10 minutes, and the material is discharged;
[0085] Step 6: The granules in step 5 are tableted using a rotary tablet press, and the tablet hardness is controlled at 60N.
[0086] Example 4
[0087] This embodiment provides a method for preparing a bumetanide composition, wherein the raw materials include:
[0088]
[0089] The preparation method thereof comprises:
[0090] Step 1: Preliminarily mix 2 g of bumetanide, 2 g of talc, and 2 g of silicon dioxide, and then grind them into a particle size D90≤15 μm using a jet mill to obtain a primary mixed raw material;
[0091] Step 2: Place 3 g of the primary mixed raw materials in step 1, microcrystalline cellulose, corn starch, povidone, and magnesium oxide in a wet granulator, start stirring at a speed of 300 rpm and a shear speed of 1000 rpm and mix for 30 minutes;
[0092] Step 3: Dissolve the prescribed amount of Tween 80 with an appropriate amount of purified water, and dissolve the prescribed amount of meglumine with an appropriate amount of purified water, and set aside;
[0093] Step 4: Place the material in step 2 in a fluidized bed granulation pot, control the material temperature at 40±5°C, and then start spraying the solution in step 3 to perform boiling granulation. The material temperature is controlled at 35±5°C. After the spraying is completed, maintain the inlet air temperature at 70°C, control the granule moisture content at 4%, stop drying, and collect the material.
[0094] Step 5: The granules in step 4 are sieved through a 20-mesh sieve for granulation. After granulation, talcum powder, silicon dioxide, and magnesium stearate are added, and the mixture is mixed at a speed of 8 rpm for 12 minutes using a three-dimensional motion mixer, and the mixture is discharged;
[0095] Step 6: The granules in step 5 are tableted using a rotary tablet press, and the tablet hardness is controlled at 40N.
[0096] Example 5
[0097] This embodiment provides a method for preparing a bumetanide composition, wherein the raw materials include:
[0098]
[0099] The preparation method thereof comprises:
[0100] Step 1: Preliminarily mix 2 g of bumetanide, 2 g of talc, and 2 g of silicon dioxide, and then grind them into a particle size D90≤15 μm using a jet mill to obtain a primary mixed raw material;
[0101] Step 2: Place 3 g of the primary mixed raw materials in step 1, microcrystalline cellulose, corn starch, povidone, and magnesium oxide in a wet granulator, start stirring at a speed of 500 rpm and a shear speed of 1500 rpm and mix for 10 minutes;
[0102] Step 3: Dissolve the prescribed amount of Tween 80 with an appropriate amount of purified water, and dissolve the prescribed amount of meglumine with an appropriate amount of purified water, and set aside;
[0103] Step 4: Place the material in step 2 in a fluidized bed granulation pot, control the material temperature at 40±5°C, and then start spraying the solution in step 3 to perform boiling granulation. The material temperature is controlled at 38±5°C. After the spraying is completed, maintain the inlet air temperature at 80°C, control the granule moisture content at 8%, stop drying, and collect the material.
[0104] Step 5: The granules in step 4 are sieved through a 40-mesh sieve for granulation. After granulation, talcum powder, silicon dioxide and magnesium stearate are added, and the mixture is mixed at a speed of 12 rpm for 8 minutes using a three-dimensional motion mixer, and the mixture is discharged;
[0105] Step 6: The granules in step 5 are tableted using a rotary tablet press, and the tablet hardness is controlled at 80N.
[0106] It is worth noting that the purpose of taking 2 g of bumetanide in step 1 in Examples 1-5 of the present application is to avoid grinding losses, and taking 3 g of the primary mixed raw material in step 2 can ensure that the content of bumetanide in the final product is 1 g.
[0107] Comparative Example 1
[0108] This comparative example provides a bumetanide composition, in which the stabilizer in the raw material is vitamin C, and the bumetanide is not pre-milled by air flow.
[0109] Specifically, its raw materials include:
[0110]
[0111] The preparation method thereof comprises:
[0112] Step 1: Place bumetanide, microcrystalline cellulose, corn starch, povidone, and vitamin C in a wet granulator at a stirring speed of 400 rpm and a shear speed of 1200 rpm and mix for 10 minutes;
[0113] Step 2: Dissolve the prescribed amount of Tween 80 in purified water and set aside;
[0114] Step 3: Place the material in step 1 in a fluidized bed granulation pot, control the material temperature at 40±5°C, and then start spraying the solution in step 3 to perform boiling granulation. The material temperature is controlled at 30±5°C. After the spraying is completed, maintain the inlet air temperature at 75°C, control the granule moisture content at 6%, stop drying, and collect the material.
[0115] Step 4: The granules in step 3 are sieved through a 30-mesh sieve for granulation. After granulation, talcum powder, silicon dioxide and magnesium stearate are added, and the mixture is mixed at a speed of 10 rpm for 10 minutes using a three-dimensional motion mixer, and the mixture is discharged;
[0116] Step 5: The granules in step 4 are tableted using a rotary tablet press, and the tablet hardness is controlled at 60N.
[0117] Comparative Example 2
[0118] This comparative example provides a bumetanide composition, the raw materials of which are the same as those of Example 1, except that the preparation method does not perform air flow grinding on bumetanide.
[0119] Specifically, the preparation method includes:
[0120] Step 1: Place bumetanide, microcrystalline cellulose, corn starch, povidone, magnesium oxide, and meglumine in a wet granulator and mix for 10 minutes at a stirring speed of 400 rpm and a shear speed of 1200 rpm;
[0121] Step 2: Dissolve the prescribed amount of Tween 80 in purified water and set aside;
[0122] Step 3: Place the material in step 1 in a fluidized bed granulation pot, control the material temperature at 40±5°C, and then start spraying the solution in step 3 to perform boiling granulation. The material temperature is controlled at 30±5°C. After the spraying is completed, maintain the inlet air temperature at 75°C, control the granule moisture content at 6%, stop drying, and collect the material.
[0123] Step 4: The granules in step 3 are sieved through a 30-mesh sieve for granulation. After granulation, talcum powder, silicon dioxide and magnesium stearate are added, and the mixture is mixed at a speed of 10 rpm for 10 minutes using a three-dimensional motion mixer, and the mixture is discharged;
[0124] Step 5: The granules in step 4 are tableted using a rotary tablet press, and the tablet hardness is controlled at 60N.
[0125] Comparative Example 3
[0126] This comparative example is substantially the same as Example 1, except that, in this comparative example, the bumetanide, talc, and silica in step 1 are mixed by ball milling, and the particle size D90 after grinding is 46 μm.
[0127] Comparative Example 4
[0128] This comparative example is substantially the same as Example 1, except that in this comparative example, in step 1, only bumetanide is pulverized by a jet mill to a particle size D90≤30 μm. Talc and silicon dioxide are added together only in step 5.
[0129] Comparative Example 5
[0130] This comparative example is substantially the same as Example 1, except that the stabilizers magnesium oxide and meglumine are omitted in this comparative example.
[0131] Comparative Example 6
[0132] This comparative example is substantially the same as Example 1, except that in this comparative example, the stabilizer only includes magnesium oxide, and meglumine is omitted.
[0133] Comparative Example 7
[0134] This comparative example is substantially the same as Example 1, except that in this comparative example, the stabilizer only includes meglumine, and magnesium oxide is omitted.
[0135] Comparative Example 8
[0136] This comparative example is substantially the same as Example 1, except that in this comparative example, the stabilizer contains 1 g of magnesium oxide and 5 g of meglumine.
[0137] Experimental example
[0138] The original samples of bumetanide tablets prepared in the above examples and comparative examples were placed at high temperature (60°C) for 30 days, accelerated (40°C) for 6 months, and long-term (30°C) for 6 months, and N-nitrosamine bumetanide impurities were detected. Among them, the reference preparation of bumetanide tablets was purchased from a foreign original manufacturer.
[0139] N-nitrosamine bumetanide impurity detection method:
[0140] instrument:
[0141] HPLC or UHPLC system with temperature-controlled autosampler and column compartment
[0142] Q ExactiveTM mass spectrometer (Thermo Fisher Scientific)
[0143] HPLC column: InfinityLab Poroshell 120 EC-C18, 2.7 m 120 in, 50 x 3.0 mm
[0144] Chromatographic conditions:
[0145]
[0146] Mass spectrometry conditions:
[0147] Sheath gas flow rate 50 arbitrary units Auxiliary gas flow rate 15 arbitrary units Purge gas flow rate 0 units Spray voltage 3.5 kV Capillary temperature. 300 degrees Celsius Auxiliary gas heater temperature. 350 degrees Celsius
[0148] factor n-nitrosobumetanide Scan Type Portable radiation monitor Scan start-end (minutes) 4.6 – 5.7 PRM Quarantine 394.1067 NCE 20 Isolation Window 1.0m / z Micro Scan 1 solve 140,000 AGC Target 1e6 Maximum 200ms
[0149] Pharmaceutical sample preparation:
[0150] Take an appropriate amount of the reference formulation of bumetanide tablets, examples 1-5 and comparative examples 1-8 of bumetanide tablets, grind them finely, weigh an appropriate amount to make the target concentration of the raw material in methanol reach 1.0 mg / mL, and transfer to a 15 mL glass centrifuge tube. Add an appropriate volume of methanol and mix using a vortex mixer for about one minute and shake for 40 minutes. After extraction, centrifuge the sample at 3000 rpm for 15 minutes. Filter the supernatant using a filter. Place a 0.22 μm PVDF syringe filter into an HPLC sample bottle for LC / MS analysis.
[0151] Calculation formula: ; Wherein, Aspl refers to the area of the N-nitrosobumetanide peak in the sample solution; As refers to the average peak area of the N-nitrosobumetanide reference solution (n = 6); Cs refers to the concentration of N-nitrosobumetanide in the standard solution (ng / mL).
[0152] The data is summarized as follows:
[0153] Table 1 Comparison of high temperature (60°C) tests
[0154]
[0155] Table 2 Comparison of accelerated (40°C) tests
[0156]
[0157] Table 3 Comparison of long-term (30°C) tests
[0158]
[0159] As can be seen from Table 1, under the high temperature conditions of Examples 1-5 of the present invention, the impurity content of N-nitrosamine bumetanide impurities at 0 days and 30 days at high temperature does not change much. Compared with the reference preparation of bumetanide tablets, whether it is 0 days or 30 days at high temperature, the impurity content is significantly reduced. At the same time, Comparative Example 1 uses vitamin C as a stabilizer, which has a certain effect compared with the reference preparation of bumetanide tablets, but its effect is still significantly worse than that of Example 1. The raw materials in Comparative Example 2 are the same as those in Example 1, but bumetanide is not subjected to air flow pulverization. It can be seen that at this time, its effect is improved compared with Comparative Example 1, but it is still significantly worse than that of Example 1. Comparative Example 3 can be seen that after the raw materials are pulverized, the growth of impurities is inhibited, but the growth rate of impurities is still relatively fast, and its effect is still worse than that of Example 1. Comparative Example 4 can be seen that after the raw materials are pulverized to a suitable particle size, the growth of impurities is significantly inhibited, but the overall trend is still increasing. It may be that there is no silica and talc to assist in the pulverization process, resulting in a wider overall particle size distribution. It can be seen from Comparative Example 5 that magnesium oxide and meglumine are not added to the prescription, and only the particle size control cannot achieve the purpose of inhibiting the growth of impurities. It can be seen from Comparative Example 6 that only magnesium oxide is used as an inhibitor, which can effectively inhibit the growth of impurities at a specified particle size, but it cannot completely prevent the growth. In Comparative Example 7, only meglumine is used as an inhibitor, and its inhibitory effect is poor, but in the embodiment, magnesium oxide and meglumine are mixed, and its effect plays a synergistic role, which is significantly better than Comparative Example 6 and Comparative Example 7. It can be seen from Comparative Example 8 that within the specified particle size range, the change in the ratio of magnesium oxide to meglumine can still effectively inhibit the growth of impurities, but there is still a growth trend.
[0160] As can be seen from Table 2 and Table 3, the impurity content of N-nitrosamine bumetanide impurities under accelerated (40°C) and long-term (30°C) conditions in Examples 1-5 of the present invention does not change much at 0 days and accelerated and long-term 6 months. Compared with the reference preparation of bumetanide tablets, whether it is 0 days or accelerated and long-term 6 months, the impurity level of N-nitrosamine bumetanide is significantly lower. At the same time, in Comparative Examples 1 to 3, when the raw materials are not pulverized or the pulverized particle size does not reach a certain limit, the growth of N-nitrosamine bumetanide impurities is more obvious; in Comparative Example 4, when only the raw materials are pulverized separately, the particle size distribution is too wide, and the growth of N-nitrosamine bumetanide impurities under accelerated conditions is still relatively fast; in Comparative Example 5, when no inhibitor is added, the impurity growth is relatively obvious under various stability conditions; in Comparative Examples 6 to 8, when the ratio of magnesium oxide and meglumine changes, the impurity inhibition effect is still significantly weaker than that of the embodiment.
[0161] In summary, the preparation method of the bumetanide composition provided by the present invention improves the raw materials and methods, adds a small amount of magnesium oxide and meglumine as a stabilizer, and grinds bumetanide, part of talc, and part of dioxide by a jet mill, so that a primary mixed raw material with a particle size D90≤30μm can be obtained. By controlling the particle size of the primary mixed raw material, it is beneficial to increase its surface area and ensure that the raw material and the alkalizing agent excipient are in more effective contact; then boiling granulation is performed with other excipients, so that the N-nitrosamine bumetanide impurities of the product can be significantly reduced during the preparation process and subsequent stability placement process. Under various investigation conditions, the N-nitrosamine bumetanide impurities have no significant changes compared with 0 days, ensuring the safety of the product. The generation of N-nitrosamine bumetanide impurities during the preparation and storage process can be effectively inhibited, and the safety and effectiveness of the medication can be significantly improved.
[0162] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. A method for preparing a bumetanide composition, It is characterized in that The raw materials of the bumetanide composition are composed of bumetanide: microcrystalline cellulose: corn starch: povidone: stabilizer: talc: silicon dioxide: Tween 80: magnesium stearate in a mass ratio of 1:40-80:80-140:4-12:4-9:4-10:6-10:0.5:0.5-2.5; the stabilizer is composed of magnesium oxide and meglumine, and the mass ratio of magnesium oxide to meglumine in the stabilizer is 1-10:1-3; The preparation method comprises: S1: Bumetanide, part of talc and part of silicon dioxide are preliminarily mixed and then crushed by a jet mill to a particle size D90≤30 μm to obtain a primary mixed raw material; the amount of the part of talc accounts for 30%-50% of the total amount of talc, and the amount of the part of silicon dioxide accounts for 20%-40% of the total amount of silicon dioxide; S2: mixing the primary mixed raw materials, microcrystalline cellulose, corn starch, povidone, stabilizer and Tween 80 for boiling granulation to obtain blended granules; obtaining the blended granules in step S2 comprises: firstly wet granulating the primary mixed raw materials, microcrystalline cellulose, corn starch, povidone and magnesium oxide to obtain first granules; then placing the first granules in a fluidized bed granulation pot, controlling the temperature of the first granules at 35-45° C. and then spraying Tween 80 solution to perform boiling granulation; the meglumine is added as dry powder during wet granulation, or is prepared into a solution during boiling granulation and added together with the Tween 80; S3: granulating the blended particles, adding the remaining talcum powder, the remaining silicon dioxide and magnesium stearate after granulating, and mixing them evenly to obtain a granular product.
2. The method for preparing the bumetanide composition according to claim 1, It is characterized in that The mass ratio of magnesium oxide to meglumine in the stabilizer is 5 to 8:
1.
3. The method for preparing the bumetanide composition according to claim 1, It is characterized in that The stirring speed during the wet granulation is 300-500 rpm, the shearing speed is 1000-1500 rpm, and the mixing time is 10-30 min.
4. The method for preparing the bumetanide composition according to claim 1, It is characterized in that During the boiling granulation, the material temperature is maintained at 25° C. to 42° C.; after the liquid spraying is completed, the air inlet temperature is maintained at 70° C. to 80° C., and after the moisture content of the particles is controlled at 4% to 8%, the drying is stopped and the material is collected.
5. The method for preparing the bumetanide composition according to claim 1, It is characterized in that The granulation comprises passing the blended particles through a 20-40 mesh sieve.
6. A bumetanide composition, It is characterized in that The invention is prepared by the preparation method according to any one of claims 1 to 5.
7. The bumetanide composition according to claim 6, It is characterized in that The dosage form of the bumetanide composition is granules, capsules or tablets.
Citation Information
Patent Citations
Safety rocket bomb for weather modification
CN101451799A
Pharmaceutical composition of azelnidipine
CN104473888A
Implant and method for testing drug release amount thereof
CN117017897A
Solubilization of Meloxicam and Its ManufacturingMethod
KR1020040000927A
Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
US20020044968A1
